Erenumab in the Treatment of Migraine

References

• World Health Organization: headache disorders ( 2016 ). www.who.int/mediacentre/factsheets/fs277/en/ .
   Google Scholar
• Center Disease of Control . Summary health statistics: National Health Interview Survey, 2016 ( 2016 ). https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2016_SHS_Table_A-5.pdf .
   Google Scholar
• Headache Classification Committee of the International Headache Society (IHS) . The International Classification of Headache Disorders, (3rd edition) . Cephalalgia38 ( 1 ), 1 – 211 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Ashina S , SerranoD , LiptonRBet al. Depression and risk of transformation of episodic to chronic migraine . J. Headache Pain13 ( 8 ), 615 – 624 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Disease GBD , InjuryI , PrevalenceC . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 . Lancet390 ( 10100 ), 1211 – 1259 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Burch RC , LoderS , LoderE , SmithermanTA . The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies . Headache55 ( 1 ), 21 – 34 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hawkins K , WangS , RupnowM . Direct cost burden among insured US employees with migraine . Headache48 ( 4 ), 553 – 563 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Stokes M , BeckerWJ , LiptonRBet al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS) . Headache51 ( 7 ), 1058 – 1077 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bloudek LM , StokesM , BuseDCet al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS) . J. Headache Pain13 ( 5 ), 361 – 378 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Giamberardino MA , MartellettiP . Emerging drugs for migraine treatment . Expert Opin. Emerg. Drugs20 ( 1 ), 137 – 147 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Silberstein SD . Preventive migraine treatment . Continuum (Minneap. Minn.)21 ( 4 Headache ), 973 – 989 ( 2015 ).
   PubMedGoogle Scholar
• Lionetto L , MartellettiP . Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations . J. Headache Pain16 ( Suppl. 1 ), A36 ( 2015 ).
   PubMedGoogle Scholar
• Benemei S , NicolettiP , CaponeJA , GeppettiP . Pain pharmacology in migraine: focus on CGRP and CGRP receptors . Neurol. Sci.28 ( Suppl. 2 S2 ), S89 – S93 ( 2007 ).
   PubMedGoogle Scholar
• Bigal ME , WalterS , RapoportAM . Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development . Headache53 ( 8 ), 1230 – 1244 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Brain SD , GrantAD . Vascular actions of calcitonin gene-related peptide and adrenomedullin . Physiol. Rev.84 ( 3 ), 903 – 934 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Capuano A , GrecoMC , NavarraP , TringaliG . Correlation between algogenic effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin-induced sensitization . Eur. J. Pharmacol.740 , 97 – 102 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Amara SG , JonasV , RosenfeldMG , OngES , EvansRM . Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products . Nature298 ( 5871 ), 240 – 244 ( 1982 ).
   PubMed Web of Science ®Google Scholar
• Gibbins IL , FurnessJB , CostaM , MacIntyreI , HillyardCJ , GirgisS . Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs . Neurosci. Lett.57 ( 2 ), 125 – 130 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Lundberg JM , Franco-CerecedaA , HuaX , HokfeltT , FischerJA . Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin . Eur. J. Pharmacol.108 ( 3 ), 315 – 319 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Mulderry PK , GhateiMA , BishopAE , AllenYS , PolakJM , BloomSR . Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat . Regul. Pept.12 ( 2 ), 133 – 143 ( 1985 ).
   PubMedGoogle Scholar
• Carpenter KA , SchmidtR , von MentzerB , HaglundU , RobertsE , WalpoleC . Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains . Biochemistry40 ( 28 ), 8317 – 8325 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Breeze AL , HarveyTS , BazzoR , CampbellID . Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics . Biochemistry30 ( 2 ), 575 – 582 ( 1991 ).
   PubMed Web of Science ®Google Scholar
• Conner AC , HayDL , HowittSGet al. Interaction of calcitonin-gene-related peptide with its receptors . Biochem. Soc. Trans.30 ( 4 ), 451 – 455 ( 2002 ).
   PubMedGoogle Scholar
• Chang CP , PearseRV2nd , O’ConnellS , RosenfeldMG . Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain . Neuron11 ( 6 ), 1187 – 1195 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Fluhmann B , MuffR , HunzikerW , FischerJA , BornW . A human orphan calcitonin receptor-like structure . Biochem. Biophys. Res. Commun.206 ( 1 ), 341 – 347 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Aiyar N , RandK , ElshourbagyNAet al. A cDNA encoding the calcitonin gene-related peptide type 1 receptor . J. Biol. Chem.271 ( 19 ), 11325 – 11329 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• McLatchie LM , FraserNJ , MainMJet al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor . Nature393 ( 6683 ), 333 – 339 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Muff R , LeuthauserK , BuhlmannN , FoordSM , FischerJA , BornW . Receptor activity modifying proteins regulate the activity of a calcitonin gene-related peptide receptor in rabbit aortic endothelial cells . FEBS Lett.441 ( 3 ), 366 – 368 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Choksi T , HayDL , LegonSet al. Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines . Br. J. Pharmacol.136 ( 5 ), 784 – 792 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Hagner S , HaberbergerRV , OverkampD , HoffmannR , VoigtKH , McGregorGP . Expression and distribution of calcitonin receptor-like receptor in human hairy skin . Peptides23 ( 1 ), 109 – 116 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Luebke AE , DahlGP , RoosBA , DickersonIM . Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay . Proc. Natl Acad. Sci. USA93 ( 8 ), 3455 – 3460 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Evans BN , RosenblattMI , MnayerLO , OliverKR , DickersonIM . CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors . J. Biol. Chem.275 ( 40 ), 31438 – 31443 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Supowit SC , KatkiKA , HeinTWet al. Vascular reactivity to calcitonin gene-related peptide is enhanced in subtotal nephrectomy-salt induced hypertension . Am. J. Physiol. Heart Circ. Physiol.301 ( 3 ), H683 – H688 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Prado MA , Evans-BainB , OliverKR , DickersonIM . The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction . Peptides22 ( 11 ), 1773 – 1781 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Ray BS , WolffHG . Experimental studies on headache: pain-sensitive structures of the head and their significance in headache . Arch. Surg.41 ( 4 ), 813 – 856 ( 1940 ).
   Google Scholar
• Edvinsson L , EkmanR , JansenI , McCullochJ , UddmanR . Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects . J. Cereb. Blood Flow Metab.7 ( 6 ), 720 – 728 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Eftekhari S , WarfvingeK , BlixtFW , EdvinssonL . Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system . J. Pain14 ( 11 ), 1289 – 1303 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Oliver KR , WainwrightA , EdvinssonL , PickardJD , HillRG . Immunohistochemical localization of calcitonin receptor–like receptor and receptor activity–modifying proteins in the human cerebral vasculature . J. Cereb. Blood Flow Metab.22 ( 5 ), 620 – 629 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , CharbitAR , AndreouAP , AkermanS , HollandPR . Neurobiology of migraine . Neuroscience161 ( 2 ), 327 – 341 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Edvinsson L . The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine . Headache57 ( Suppl. 2 ), 47 – 55 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Eftekhari S , SalvatoreCA , CalamariA , KaneSA , TajtiJ , EdvinssonL . Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion . Neuroscience169 ( 2 ), 683 – 696 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Strassman AM , WeissnerW , WilliamsM , AliS , LevyD . Axon diameters and intradural trajectories of the dural innervation in the rat . J. Comp. Neurol.473 ( 3 ), 364 – 376 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ . Pathophysiology of migraine . Neurol. Clin.27 ( 2 ), 335 – 360 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Durham PL . Calcitonin gene-related peptide (CGRP) and migraine . Headache46 ( Suppl 1 ), S3 – S8 ( 2006 ).
   PubMedGoogle Scholar
• Moore EL , SalvatoreCA . Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine . Br. J. Pharmacol.166 ( 1 ), 66 – 78 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Capuano A , De CoratoA , LisiL , TringaliG , NavarraP , Dello RussoC . Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology . Mol. Pain5 , 43 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• De Corato A , LisiL , CapuanoAet al. Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1β pro-inflammatory effects . J. Neuroimmunol.237 ( 1–2 ), 39 – 46 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Raddant AC , RussoAF . Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation . Expert Rev. Mol. Med.13 , e36 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Theoharides TC , DonelanJ , Kandere-GrzybowskaK , KonstantinidouA . The role of mast cells in migraine pathophysiology . Brain Res. Brain Res. Rev.49 ( 1 ), 65 – 76 ( 2005 ).
   PubMedGoogle Scholar
• Lassen LH , HaderslevPA , JacobsenVB , IversenHK , SperlingB , OlesenJ . CGRP may play a causative role in migraine . Cephalalgia22 ( 1 ), 54 – 61 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Lassen LH , JacobsenVB , HaderslevPAet al. Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients . J. Headache Pain9 ( 3 ), 151 – 157 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ashina M , BendtsenL , JensenR , SchifterS , OlesenJ . Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks . Pain.86 ( 1–2 ), 133 – 138 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E , LarrosaD , RamonC , VegaJ , Martinez-CamblorP , PascualJ . Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine . Neurology81 ( 14 ), 1191 – 1196 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , EdvinssonL . The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats . Ann. Neurol.33 ( 1 ), 48 – 56 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E , RamónC , Martínez-CamblorP , Serrano-PertierraE , LarrosaD , PascualJ . OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine . Pain156 ( 5 ), 820 – 824 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Cady RK , VauseCV , HoTW , BigalME , DurhamPL . Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan . Headache49 ( 9 ), 1258 – 1266 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cady R , TurnerI , DexterK , BeachME , CadyR , DurhamP . An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine . Headache54 ( 2 ), 269 – 277 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Doods H , HallermayerG , WuDet al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist . Br. J. Pharmacol.129 ( 3 ), 420 – 423 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Olesen J , DienerHC , HusstedtIWet al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine . N. Engl. J. Med.350 ( 11 ), 1104 – 1110 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Rudolf K , EberleinW , EngelWet al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]car bonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine . J. Med. Chem.48 ( 19 ), 5921 – 5931 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Williams TM , StumpCA , NguyenDNet al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead . Bioorg. Med. Chem. Lett.16 ( 10 ), 2595 – 2598 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Paone DV , ShawAW , NguyenDNet al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974) . J. Med. Chem.50 ( 23 ), 5564 – 5567 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Salvatore CA , HersheyJC , CorcoranHAet al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine . J. Pharmacol. Exp. Ther.324 ( 2 ), 416 – 421 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Ho TW , FerrariMD , DodickDWet al. Articles efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial . Lancet372 ( 9656 ), 2115 – 2123 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Connor KM , ShapiroRE , DienerHCet al. Randomized, controlled trial of telcagepant for the acute treatment of migraine . Neurology73 ( 12 ), 970 – 977 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ho TW , ConnorKM , ZhangYet al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention . Neurology83 ( 11 ), 958 – 966 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Negro A , LionettoL , SimmacoM , MartellettiP . CGRP receptor antagonists: an expanding drug class for acute migraine?Expert Opin. Investig. Drugs.21 ( 6 ), 807 – 818 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Salvatore CA , MooreEL , CalamariAet al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist . J. Pharmacol. Exp. Ther.333 ( 1 ), 152 – 160 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Hewitt DJ , AuroraSK , DodickDWet al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine . Cephalalgia31 ( 6 ), 712 – 722 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Degnan AP , ChaturvedulaPV , ConwayCMet al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5 -yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxami de (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure . J. Med. Chem.51 ( 16 ), 4858 – 4861 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Voss T , LiptonRB , DodickDWet al. A Phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine . Cephalalgia36 ( 9 ), 887 – 898 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Joel Trugman MF , RichardLipton , DavidDodick , KaifengLu , HassanLakkis , ArminSzegedi . Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: results from a single attack Phase II study . ACHIEVE I. ( 2018 ). www.aan.com/conferences-community/annual-meeting/abstracts-and-awards/emerging-science/ .
   Google Scholar
• Marcus R , GoadsbyPJ , DodickD , StockD , ManosG , FischerTZ . BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial . Cephalalgia34 ( 2 ), 114 – 125 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hollenstein K , de GraafC , BortolatoA , WangMW , MarshallFH , StevensRC . Insights into the structure of class B GPCRs . Trends Pharmacol. Sci.35 ( 1 ), 12 – 22 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shi L , LehtoSG , ZhuDXet al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor . J. Pharmacol. Exp. Ther.356 ( 1 ), 223 – 231 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Muff R , StanglD , BornW , FischerJA . Comparison of a calcitonin gene-related peptide receptor in a human neuroblastoma cell line (SK-N-MC) and a calcitonin receptor in a human breast carcinoma cell line (T47D) . Ann. N. Y. Acad. Sci.657 , 106 – 116 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Zhou H , MascelliMA . Mechanisms of monoclonal antibody–drug interactions . Annu. Rev. Pharmacol. Toxicol.51 , 359 – 372 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Gerber DE . Targeted therapies: a new generation of cancer treatments . Am. Fam. Physician77 ( 3 ), 311 – 319 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Xu Y , GabrielK , WangYet al. A multicenter, open-label, pharmacokinetic drug interaction study of erenumab (AMG 334) and a combined oral contraceptive in healthy female subjects . Headache57 ( S3 ), 192 – 193 ( 2017 ).
   Google Scholar
• Vu T , MaP , ChenJSet al. Pharmacokinetic–pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects . Pharm. Res.34 ( 9 ), 1784 – 1795 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• de Hoon J , Van HeckenA , VandermeulenCet al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine . Clin. Pharmacol. Ther.103 ( 5 ), 815 – 825 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Sun H , DodickDW , SilbersteinSet al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, Phase II trial . Lancet Neurol.15 ( 4 ), 382 – 90 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Tepper S , AshinaM , ReuterUet al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled Phase II trial . Lancet Neurol.16 ( 6 ), 425 – 434 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , ReuterU , HallstromYet al. A controlled trial of erenumab for episodic migraine . N. Engl. J. Med.377 ( 22 ), 2123 – 2132 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Dodick DW , AshinaM , BrandesJLet al. ARISE: a Phase III randomized trial of erenumab for episodic migraine . Cephalalgia38 ( 6 ), 1026 – 1037 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Ashina M , DodickD , GoadsbyPJet al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study . Neurology89 ( 12 ), 1237 – 1243 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Zhou Z , PengJ , WangCJet al. Accelerated senescence of endothelial progenitor cells in hypertension is related to the reduction of calcitonin gene-related peptide . J. Hypertens.28 ( 5 ), 931 – 939 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• de Hoon J , Van HeckenA , VandermeulenCet al. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy subjects . Neurology88 ( 16 ), P2.161 ( 2017 ).
   Google Scholar
• Depre C , AntalikL , StarlingAet al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina . Headache58 ( 5 ), 715 – 723 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Ashina M DD , GoadsbyPJ , KudrowDet al. Efficacy of erenumab for the treatment of patients with chronic migraine and aura . Cephalalgia37 ( 1S ), 34 – 35 ( 2017 ).
   Google Scholar
• Tepper SJ DH , AshinaM , BrandesJLet al. Efficacy of erenumab for the treatment of patients with chronic migraine in presence of medication overuse . Cephalalgia37 ( 1S ), 33 – 34 ( 2017 ).
   Google Scholar
• Reuter U TS , McallisterP , AshinaMet al. Early onset of efficacy in a Phase II clinical trial of erenumab in patients with chronic migraine . Cephalalgia37 ( 1S ), 35 – 36 ( 2017 ).
   Google Scholar
• A study evaluating the effectiveness of AMG 334 injection in preventing migraines in adults having failed other therapies (LIBERTY) ( 2018 ). https://clinicaltrials.gov/ct2/show/NCT03096834?term=03096834&rank=1 .
   Google Scholar
• Reuter U , GoadsbyP , Lanteri-MinetM , FerrariM , WenS , KlattJ . Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: results from the Phase 3b LIBERTY study . Neurology90 ( 24 ), e2186 – e2187 ( 2018 ).
   Google Scholar
• FDA approves Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention ( 2018 ). www.amgen.com/media/news-releases .
   Google Scholar